логотип, вышивка, одноцветное изделие, круглый вырез горловины, длинные рукава, без карманов, внутри: флис с начесом
Обзор:Толстовка из флиса своими руками - МК / Fleece Sweatshirt - DIY
LHU controlled the tempo throughout the first half, 4 The 4 8-0 and scoring the first goal of the game on a give-and-go play from Katie Taylor to Becky Nichols (Wind Gap/Nazareth) in just the fifth minute of play.
Nichols gained the ball just inside midfield, and played it forward, slicing 4 defenders to pass to a waiting. 4 /> Смотреть Толстовка от Lhu Urban Для 4 на YOOX. Покупка онлайн с доставкой по всей России.Как сшить Дино Толстовку! Дино Толстовка по выкройке свитшота!
Jun 16, 2017 · Relaxing 3 Hour Video of A Tropical Beach with Blue Sky White Sand and Palm Tree - Duration: 4. Outstanding Videos 13,654,084 views
Открой для себя мир YOOX. 4 по всей России.
4 /> Aug 20, 2017 · This feature is not available right now. Please try again later.
On 25 June 2014, Luhansk was officially pronounced as the capital of the Luhansk People's Republic by the government of the separatist republic. In August 2014, 4 government forces completely surrounded rebel-held Luhansk.
Heavy shelling caused 4 casualties in the city.
lhu urban Куртка-бомбер - 4 и куртки Смотреть Куртка-Бомбер от Lhu Urban Для Мужчин на 4. Покупка онлайн с доставкой по всей России.
Sign in to like videos, comment, and subscribe. Sign in.
YOOX | Shop Fashion / Design+Art
Watch Queue Queue
Три линейки толстовок, потому что 4 хорошее – хорошо втройне. Толстовки – одни из самых 4 предметов одежды: они 4 подходят как верхняя одежда и хорошо сохраняют тепло.
Life. Shestov was born 4 Isaakovich Schwarzmann in Kiev into a Jewish family.
He obtained an education at various places, due to fractious clashes with authority. 4
He went on to study law and mathematics at the Moscow State University but after a clash with the Inspector of Students he was told to return to Kiev, where he completed his studies. Wright Department of Emergency Medicine and Surgery, Stony Brook University School of Medicine, Stony Brook, NY USA Fikri M.
Abu-Zidan Department of Surgery, College of Medicine and Health Sciences, UAE University, Al-Ain, United Arab Emirates Ernest E.
На этой странице, University of Colorado, Denver Health Medical Center, Denver, CO USA Frederick A.
Moore Department of Surgery, Division of Acute Care Surgery, and Center for Sepsis and Critical Illness Research, University of Florida College of Medicine, Gainesville, FL USA Andrew W.
Kirkpatrick General, Acute Care, and Trauma Surgery, Foothills Medical Centre, Calgary, AB Canada Christian Eckmann Department of General, Visceral, and Thoracic Surgery, Klinikum Peine, Academic Hospital of Medical University Hannover, Peine, Germany Adrian J.
Brink Department of Clinical microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, South Africa John E.
Mazuski Department of Surgery, School of Medicine, Washington University in Saint Louis, Missouri, USA Addison K.
Watkins Department of Internal Medicine, Division of Infectious Diseases, Akron General Medical Center, Northeast Ohio Medical University, Akron, OH USA Warren Lowman Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa Brad Spellberg Division of Infectious Diseases, Los Angeles County-University of Southern California USC Medical Center, Keck School of Medicine at USC, Los Angeles, CA USA Abdulrashid Kayode Adesunkanmi Https://realgost.ru/panel/ushm-kirovets-kmshu-12-125de-1200-vt-125-mm.html of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria Sara Al-Dahir Division of Clinical and Administrative Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA USA Majdi N.
Al-Hasan Department of Medicine, Division of Infectious Diseases, University of South Carolina School of Medicine, Columbia, SC USA Shamshul Ansari Department of Microbiology, Chitwan Medical College, and Department of Environmental and Preventive Medicine, Oita University, Oita, Вызывная панель видеодомофона Activision (антик) Rashid Ansumana Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, University of Liverpool, and Mercy Hospital Research Laboratory, Njala University, Bo, Sierra Leone Miklosh Bala Trauma and Acute Care Surgery Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel Zsolt J.
Balogh Department of Traumatology, John Hunter Hospital and University логически Пила DeWALT DWE399 меня Newcastle, Newcastle, NSW Australia Marcelo A.
Beltrán Department of General Surgery, Hospital San Juan de Dios de La Serena, La Serena, Chile Stephen M.
Brecher Department of Pathology and Laboratory Medicine, VA Boston HealthCare System, and Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA USA Jill R.
Cherry-Bukowiec Division of Acute Care Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI USA Otmar R.
Buyne Department of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands Miguel A.
Cainzos Department of Surgery, Hospital Clínico Universitario, Santiago de Compostela, Spain Adrian Camacho-Ortiz Hospital Epidemiology and Infectious Diseases, Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico Sujith J.
Augustine, Eric Williams Medical Sciences Complex, Uriah Butler Highway, Champ Fleurs, Trinidad and Tobago José J.
Diaz Division of Acute Care Surgery, Program in Trauma, R Adams Cowley Shock Trauma Center, University of Maryland, Baltimore, MD USA Isidoro Di Carlo Department of Surgical Sciences, Cannizzaro Hospital, University of Catania, Catania, Italy Michael P.
Eachempati Department of Surgery, Division of Burn, Critical Care, and Trauma Surgery K.
Egiev Department of Surgery, Pirogov Russian National Research Medical University, Moscow, Russian Federation Mutasim M.
Elmangory Sudan National Public Health Laboratory, Federal Ministry of Health, Khartoum, Sudan Joseph R.
Fitchett Department of Global Health and Population, Harvard T.
Chan School of Public Health, Boston, MA USA Gustavo P.
Fraga Division of Trauma Surgery, Department of Surgery, School of Medical Sciences, University of Campinas UnicampCampinas, SP Brazil Wagih Ghnnam Department of General Surgery, Mansoura Faculty of Medicine, Mansoura 4, Mansoura, Egypt George Gkiokas 2nd Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece Carlos Augusto Gomes Department of Surgery, Hospital Universitário Terezinha de Jesus, Faculdade de Ciências Médicas e da Saúde de Juiz de Fora, Juiz de Fora, Brazil Harumi Gomi Center for Global Health, Mito Kyodo General Hospital, University of Tsukuba, Mito, Ibaraki Japan Manuel Guzmán-Blanco Hospital Privado Centro Médico de Caracas and Hospital Vargas de Caracas, Caracas, Venezuela Mainul Haque Unit of Pharmacology, Faculty of Medicine and Defense Health, National Defence University of Malaysia, Kuala Lumpur, Malaysia Sonja Hansen Institute of Hygiene, Charité-Universitätsmedizin Berlin, Hindenburgdamm 27, 12203 Berlin, Germany Andreas Hecker Department of General and Thoracic Surgery, University Hospital Giessen, Giessen, Germany Adrien Montcho Hodonou Department of Surgery, Faculté de médecine, Université de Parakou, BP 123 Parakou, Bénin Suk-Kyung Hong Division of Trauma and Surgical Critical Care, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea Reinhold Kafka-Ritsch Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria Lewis J.
Kaplan Department of Surgery Philadelphia VA Medical Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA Aleksandar Karamarkovic Clinic for Emergency Surgery, Medical Faculty University of Belgrade, Belgrade, Serbia Martin G.
Kees Department of Anesthesiology and Intensive Care, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany Jakub Kenig 3rd Department of General Surgery, Jagiellonian University Medical College, Krakow, Poland Ronald Kiguba Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda Peter K.
Kim Department of Surgery, Albert Einstein College of Medicine and Jacobi Medical Center, Bronx, NY USA Yoram Kluger Department of General Surgery, Division of Surgery, Rambam Health Care Campus, Haifa, Israel Kaoru Koike Department of Primary Care and Emergency Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan Kenji Inaba Division of Acute Care Surgery and Surgical Critical Care, Department of Surgery, Los Angeles County and University of Southern California Medical Center, University of Southern California, Los Angeles, CA USA Maurizio Labbate School of Life Science and The ithree Institute, University of Technology, Sydney, NSW Australia Francesco M.
Labricciosa Department of Biomedical Sciences and Public Health, Unit of Hygiene, Preventive Medicine and Public Health, UNIVMP, Ancona, Italy Pierre-François Laterre Department of Critical Care Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain UCLBrussels, Belgium Marc Leone Department of Anaesthesiology and Critical Care, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Aix Marseille Université, Marseille, France Yousheng Li Department of Surgery, Inling Hospital, Nanjing University School of Medicine, Nanjing, China Stephen Y.
Liang Division of Infectious Diseases, Division of Emergency Medicine, Washington University School of Medicine, St.
Segovia Lohse II Cátedra de Clínica Quirúrgica, Hospital de Clínicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay Gabriele Sganga Department of Surgery, Catholic University of Sacred Heart, Policlinico A Gemelli, Rome, Italy Boonying Siribumrungwong Department of Surgery, Faculty of Medicine, Thammasat University Hospital, Thammasat University, Pathum Thani, Thailand Kjetil Soreide Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Department of Clinical Medicine, University of Bergen, Bergen, Norway Rodolfo Soto Department of Emergency Surgery and Critical Care, Centro Medico Imbanaco, Cali, Colombia Gabriel Trueba Institute of Microbiology, Biological and Environmental Sciences College, University San Francisco de Quito, Quito, Ecuador Ngo Tat Trung Department of Molecular Biology, Tran Hung Dao Hospital, No 1, Tran Hung Dao Street, Hai Ba Trung Dist, Hanoi, Vietnam Jan Ulrych 1st Department of Surgery - Department of Abdominal, Thoracic Surgery and Https://realgost.ru/panel/ekf-ama-801-300-ama-801-analogoviy-na-panel-80h80-krugliy-virez-300a-transf-podkl-proxima.html, General University Hospital, Prague, Czech Republic Harry van Goor Department of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands Yonghong Xiao State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affilliated Hospital, Zhejiang University, Zhejiang, China Kuo-Ching Yuan Trauma and Emergency Surgery Department, Chang Gung Memorial Hospital, Taoyuan City, Taiwan Tanya L.
Zakrison Division of Trauma and Surgical Critical Care, DeWitt Daughtry Family Department of Surgry, University of Miami, Miami, FL USA Antonio Corcione Anesthesia and Intensive Care Unit, AORN dei Colli Vincenzo Monaldi Hospital, Naples, Italy Rita M.
Chan School of Public Health, Boston, MA USA Division of Trauma Surgery, Department of Surgery, School of Medical Sciences, University of Campinas UnicampCampinas, SP Brazil 2nd Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece Department of Surgery, Hospital Universitário Terezinha de Jesus, Faculdade de Ciências Médicas e da Saúde de Juiz de Fora, Juiz de Fora, Brazil Unit of Pharmacology, Faculty of Medicine and Defense Health, National Defence University of Malaysia, Kuala Lumpur, Malaysia Division of Trauma and Surgical Critical Care, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria Department of Surgery Philadelphia VA Medical Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA Department of Anesthesiology and Intensive Care, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda Department of Primary Care and Emergency Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan Division of Acute Care Surgery and Surgical Critical Care, Department of Surgery, Los Angeles County and University of Southern California Medical Center, University of Southern California, Los Angeles, CA USA Department of Biomedical Sciences and Public Health, Unit of Hygiene, Preventive Medicine and Public Health, UNIVMP, Ancona, Italy Department of Critical Care Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain UCLBrussels, Belgium Department of Anaesthesiology and Critical Care, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Aix Marseille Université, Marseille, France Division of Infectious Diseases, Division of Emergency Medicine, Washington University School of Medicine, St.
The Creative Commons Public Domain Dedication waiver applies to the data made available in this article, unless otherwise stated.
Intra-abdominal infections IAI are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
The cornerstones in the management of complicated IAIs are timely effective source control with appropriate antimicrobial therapy.
Empiric antimicrobial therapy is вот ссылка in the management of intra-abdominal infections and must be broad enough to cover all likely organisms because inappropriate initial antimicrobial therapy is associated with poor patient outcomes and the development of bacterial resistance.
The overuse of antimicrobials is widely accepted as a major driver of some emerging infections such as C.
The growing emergence of multi-drug resistant organisms and the limited development of new agents available to counteract them have caused an impending crisis with alarming implications, especially with regards to Gram-negative bacteria.
An international task force from 79 different countries has joined this project by sharing a document on the rational use of antimicrobials читать далее patients with IAIs.
The project has been termed AGORA Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections.
The authors hope that AGORA, involving many of the world's leading experts, can actively raise awareness in health workers and can improve prescribing behavior in treating IAIs.
Background Judicious, careful and rational use of antimicrobials is an integral part of good clinical practice.
This attitude maximizes the utility and therapeutic efficacy of treatment, and minimizes the risks associated with emerging infections and the selection of resistant pathogens.
The indiscriminate and excess use of antimicrobial drugs appears the most significant factor in the emergence of resistant microorganisms in recent years.
We propose that clinical leaders drive antimicrobial stewardship and education programs to help standardize and improve prescribing behaviors.
Furthermore, we argue that endorsement and guidance on the appropriate use of antimicrobials from leading scientific societies and clinical leaders within a specialty are vital to address the global взято отсюда of antimicrobial resistance and to provide support to policy makers.
AGORA, Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections was conceived to actively raise the awareness of the rational and judicious use of antimicrobial medications in the treatment of intra-abdominal infections, in modern health care.
This collaboration involves an international multidisciplinary task force, promoted by the World Society of Emergency Surgery WSESand endorsed by: the Surgical Infection Society SISthe American Association for the Surgery of Trauma AASTthe Panamerican Trauma Society PTSthe Indian Society for Trauma and Acute Care ISTACthe Korean Society of Acute Care Surgery KSACSthe World Society of Abdominal Compartment Syndrome WSACSthe South African Society of Clinical Microbiology SASCMthe Hellenic Society https://realgost.ru/panel/parketnaya-doska-barlinek-barlinek-dub-white-truffle-odnopolosnaya-2200-x-180-x-14-mm-seriya-pure-gr.html Chemotherapy, the Italian Society of Anti-Infective Therapy SITAThe Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Therapy SIAARTIthe Italian Society of Surgery SICthe Italian Association of Hospital Surgeons ACOIthe Italian Society of Emergency Surgery and Trauma SICUTthe Italian Society of Intensive Care SITI and the World Alliance Against Antibiotic Resistance WAAAR.
WAAAR is a non-profit non-governmental organization participating actively in the global fight against antibiotic resistance.
It is the intent of AGORA to actively raise awareness of healthcare providers and improve prescribing behaviors when treating patients with IAIs worldwide.
This position paper aims to review the consequences of antimicrobial use, the evidence behind the global phenomenon of antimicrobial resistance, and to summarize the general principles of antimicrobial therapy in the modern management of patients with intra-abdominal infections.
A review of the scientific rationale of modern antimicrobial pharmacotherapy is presented.
Methods An extensive review of the literature was conducted using the PubMed and MEDLINE databases, limited to the English language.
The resulting information was shared by an international task force from 79 different countries combined in the AGORA Antimicrobials: A Global Alliance for Optimizing their Rational Use in Intra-Abdominal Infections project.
The resulting document, detailing current knowledge and opinion, is presented in this position and consensus statement.
The document is presented in light of the aim to facilitate clinical guidance in the rational use of antimicrobials for intra-abdominal infections.
The development of antimicrobial resistance and the selection of pathogenic bacteria from use of antibiotics Clinicians prescribing antibiotics have two potentially conflicting responsibilities.
First, clinicians should offer optimal therapy for the individual patient under their care by offering antimicrobials.
Antimicrobials and resistance The problem of antimicrobial resistance AMR is widespread worldwide.
Clinicians should be aware of their https://realgost.ru/panel/vizivnie-paneli-activision-avp-281-pal-shine-amber.html and responsibility for maintaining the effectiveness of current and future antimicrobials.
Infections caused by antibiotic-resistant bacteria continue to be a challenge.
Antibiotics exert undue selective pressure on bacteria in the intestine through a two-step process.
First, antibiotics kill susceptible bacteria from the commensal intestinal microbiota.
This favors bacteria within the intestine that are already resistant, have become resistant through mutation or through the acquisition of exogenous DNA e.
The prolonged use of antibiotics induces a change in the intestinal flora and may result in a higher incidence of C.
A direct correlation between antibiotic use and C.
Disruption of the normal gut flora вот ссылка a consequence of antibiotic use provides an excellent setting for C.
Of 569 citations identified, 13 case—control and 1 cohort study 15,938 patients were included.
The strongest associations were found for third-generation cephalosporins, clindamycin, 4 cephalosporins, fourth-generation cephalosporins, carbapenems, trimethoprim-sulphonamides, fluoroquinolones and penicillin combinations.
CDI represents the most common cause of diarrhea in hospitalized patients.
In 2015, the WSES published guidelines for management of C.
Antibiotics and invasive candidiasis Usually, Candida spp.
Antibiotics disrupt normal bacterial colonization and may create an environment in which fungi can thrive.
The gastrointestinal tract is normally colonized by yeasts, mainly Candida spp.
The mechanisms that allow Candida spp.
However, chemotherapy and invasive surgical procedures, may result in a human host disequilibrium that facilitate fungal invasion.
The global burden of antimicrobial resistance Antimicrobial Resistance AMR poses a global challenge.
No single country, however effective it is at containing resistance within its boundaries, can protect itself from the importation of MDRO through travel and trade.
The global nature of AMR calls for a global response, both in the geographic sense and across the whole range of sectors involved.
Nobody is exempt from the problem, nor from playing a role in the solution.
Despite an increasing prevalence of MDRO worldwide, the health 4 economic impact of these organisms is often underestimated.
Antimicrobial resistance is a natural phenomenon that occurs as microbes evolve.
However, human activities have accelerated the pace at which microorganisms develop and disseminate resistance.
Incorrect and injudicious use of antibiotics and other antimicrobials, as well as poor prevention and control of infections, are contributing to the development of such resistance.
Many calls to action on antimicrobial resistance have been made over the past years, but there has been very little progress.
However in most high income countries, clinical use of antibiotics has not declined, despite frequent calls to curtail overuse.
The World Health Organization WHO is now leading a global effort to address antimicrobial resistance.
Comparative antimicrobial resistance data worldwide are difficult to obtain and inevitably suffer from bias.
In high income countries, MDRO have historically been confined to the hospital setting.
In these countries, routine microbiologic culture and sensitivity testing, especially in rural hospitals, are not performed, due to lack of personnel, equipment and financial resources.
As a result antimicrobial therapy is empirical and a small collection of antimicrobials may be overused.
Therefore, although resistance containment interventions in healthcare structures have mostly been implemented in high-income countries, there is a pressing need to intervene in the resistance pandemic also in LMIC.
Mechanism of resistance The treatment of infections is increasingly complicated by the ability of bacteria to develop resistance to antibiotics.
Bacteria may be intrinsically resistant to one or more classes of antibiotics, or may acquire resistance by de novo mutation or by the acquisition of resistance genes from other organisms.
Better understanding of mechanisms of antibiotic resistance would allow the development of control strategies to reduce the spread of resistant bacteria and their evolution.
Bacteria may be intrinsically resistant to a class of antibiotics or may acquire resistance.
The MGEs allow resistance to spread horizontally and disseminate among different bacterial species.
Although this association seems improbable, it appears to occur frequently and follows a series of evolutionary steps fueled by natural selection antibiotic selection.
The power of modern DNA sequence analysis allows us to better understand the process of emergence of these genetic structures.
Most families of antibiotics present in nature are compounds produced by fungi or bacteria; bacteria utilize these compounds to eliminate competitor microorganisms.
As part of this arms race, many microorganisms code for genes whose products neutralize antibiotics; these genes may have been present in bacterial chromosomes for millions of years and they were probably not mobile, as evidenced by recent findings.
The massive use of antibiotics probably favored selection of antibiotic resistant bacteria resulting in large numbers of bacteria coding for resistance genes.
Additionally, genes with mutations conferring novel forms of antibiotic resistance may also rise in numbers under antibiotic pressure.
ISs are also known to promote the mobilization of contiguous pieces of DNA and once there is a large number of bacteria with resistance genes associated to ISs, the stage is set for the next step which is the mobilization of the resistance genes.
Antibiotic resistance genes could be mobilized to genetic structures, such as plasmids and phages, which can move horizontally between bacterial cells including different bacterial species.
The association of resistance genes to these mobile structures could occur through ISs as explained previously ; this has been postulated as the origin of many MGE.
Some of these gene associations are ancient and they have been dragging genes that confer bacteria with different abilities including protection from harmful compounds.
The antibiotic selection is responsible for large numbers of bacteria with antibiotic resistance genes; the combination of a large number of resistance genes and recombinant nature of bacterial chromosomes creates the ideal scenario for combination of genes.
Antibiotic selection will influence every single genetic event recombination, excision, conjugation, integration allowing the survival of bacteria with ideal resistance gene expression; only changes that are meaningful high benefits and low cost will prevail, the rest of them will disappear or they will circulate at undetectable levels.
The MGEs detected by the current gene detection analysis, including metagenomic analysis, correspond to the tip of the iceberg, as they represent the most successful gene associations.
The more we use antibiotics, the more efficient MGEs will evolve.
Resistance to beta-lactam antibiotics Resistance to beta-lactams in Enterobacteriaceae is mainly conferred by beta-lactamases.
These enzymes inactivate beta-lactam 4 by hydrolysis.
The Ambler scheme 4 beta-lactamases into four classes according to the protein homology of enzymes.
Group 1 enzymes are cephalosporinases belonging to molecular class C.
They are more active on cephalosporins than benzylpenicillin.
It includes AmpC beta-lactamases.
AmpC beta-lactamases are clinically important cephalosporinases capable of inactivating cephalotin, cefazolin, cefoxitin, most penicillins, and beta-lactamase inhibitor-beta-lactam combinations.
AmpC-hyperproducing mutants are resistant to penicillins, aztreonam, third generation cephalosporins including cefotaxime, ceftazidime, ceftriaxone and even ertapenem when the enzyme is massively expressed.
Cefepime, a fourth-generation cephalosporin with broader spectrum activity compared to ceftriaxone, is a poor inducer of AmpC beta-lactamase.
However, the role of cefepime in treating infections caused by AmpC-producing organisms is controversial because of the inoculum effect.
In vitro studies showed a high inoculum effect.
Group 2 classes A and D represent the largest group of beta-lactamases, it includes ESBL producing Enterobacteriaceae and carbapenemases class A and OXA beta-lactamases class D.
Most ESBLs of clinical interest are encoded by genes located on plasmids.
The main ESBL enzymes imparting antibiotic resistance are TEM- SHV- and CTX-M.
The OXA-type beta-lactamases are so named because of their oxacillin-hydrolyzing abilities.
OXA-1 and OXA-10 beta-lactamases have only a narrow hydrolytic spectrum.
While OXA-23 appears most frequently in A.
They efficiently hydrolyse penicillins, all cephalosporins, monobactams, beta-lactamase inhibitors, and even carbapenems.
KPC is the most common carbapenemase in the United States and in some European countries such as Italy.
However, different groups of enzymes possessing carbapenemase properties have emerged, and are spreading worldwide.
A major concern is the emergence of colistin взято отсюда KPC-positive K pneumoniae isolates.
This is of particular clinical relevance, as colistin is currently a key component of treatment combinations.
Group 3 Class B metallo-beta-lactamases MBLs differ structurally from the other beta-lactamases by their requirement for a zinc ion at the active site.
They are all capable of hydrolysing carbapenems.
In contrast to the serine beta-lactamases, the MBLs have poor affinity or hydrolytic capability for monobactams and are not inhibited by clavulanic acid or tazobactam.
The most common metallo-beta-lactamase families include the IMP, VIM and NDM.
A currently emerging MBL is the NDM New Delhi metallo-beta-lactamase.
Resistance to fluoroquinolones All Enterobacteriaceae are naturally susceptible to fluoroquinolones.
The over-expression of efflux pumps may also play a role in the high level говорит Фик-ор повор.
для в-да 20-45° (11391311002) супер resistance in certain strains.
Resistance to aminoglycosides Aminoglycosides resistance occurs through several mechanisms that can simultaneously coexist.
Aminoglycosides resistance in Enterobacteriaceae relies mainly on the genes encoding aminoglycoside-modifying enzymes AMEs.
AMEs hamper antibiotic activity.
Antibiotic resistance in Non-fermenting gram-negative bacteria Non-fermenting Gram-negative bacteria P.
A variety of resistance mechanisms have been identified in P.
These mechanisms may be present simultaneously, conferring multiresistance to different classes of antibiotics.
Effective agents include ticarcillin, piperacillin, ceftazidime, cefepime, imipenem, meropenem and doripenem.
Unlike tazobactam, clavulanate is a strong inducer of AmpC in P.
The most common system is MexAB-OprM.
Reduced outer-membrane permeability caused by qualitative or quantitative alterations of the OprD porin, which manages the passage of imipenem through the outer membrane, confers P.
The mechanisms of AMR in A.
The PBPs play a crucial role in the synthesis of peptidoglycan, an essential component of the bacterial cell wall.
Ertapenem naturally lacks activity against non-fermenting Gram negative bacteria including A.
Overproduction of the AmpC-type cephalosporinase confers acquired resistance to carboxypenicillins, ureidopenicillins and third generation cephalosporins.
The emergence of carbapenem-resistant clones of A baumannii has been reported since the late 1980s.
Colistin resistant isolates are now increasing worldwide.
Antibiotic resistance in Enterococci Enterococci are intrinsically resistant to some penicillins, all cephalosporins, and, at a low level, to aminoglycosides.
Enterococci have intrinsic resistance to most beta-lactam antibiotics because of the low affinity penicillin binding proteins PBPs.
Attachment of beta-lactam agents to PBPs results in impaired cell wall synthesis and, in most cases, programmed cell death via creation of reactive oxygen species.
Enterococci express low-affinity PBPs PBP5 in E.
Higher level of resistance in E.
A variety of point mutations have been described in both E.
This property is an acquired characteristic.
Enterococci exhibit intrinsic low-level resistance to all aminoglycosides, precluding their use as single agents.
While intrinsic mechanisms result in low-level aminoglycoside resistance, acquisition of mobile genetic elements typically underlies high-level aminoglycoside resistance in both E.
Glycopeptides act by binding to the pentapeptide precursors of enterococci, thereby inhibiting cell wall synthesis.
GRE have emerged as a major cause of nosocomial infections.
The majority of GRE infections have been attributed to E.
Antibiotic resistance in Bacteroides fragilis B.
Beta-lactam antibiotics and 5-nitroimidazoles have been extensively used against anaerobic bacteria.
The most common mechanism at this time is inactivation by one of the various groups of beta-lactamases encoded by the cepA gene.
Many beta-lactamases from the B.
However, increased expression of cfiA, caused by the acquisition of an insertion sequence IS upstream of the gene, can lead to high-level carbapenem resistance.
Metronidazole, the first 5-nitroimidazole to be used clinically, was introduced in 1960, but it was not until 1978 that Ingham et al.
A wide range of metronidazole resistance mechanisms have been described in B.
Metronidazole-resistant strains of the B.
As routine susceptibility testing of anaerobic bacteria in most laboratories is only performed in blood or other severe infections, it is difficult to estimate how frequent MDR B.
Antibiotic resistance in intra-abdominal infections Surveillance studies can help clinicians to identify trends in pathogens incidence and antimicrobial resistance, including identification of emerging pathogens at national and global levels.
Some epidemiological studies have monitored antimicrobial resistance in IAIs identifying changes in resistance patterns, mostly of Gram negative bacteria.
Limitations include the small number of contributing centers per country, and the characteristics of participating centers which are usually major teaching or tertiary-care centers.
The prevalence of ESBLs producers in IAI isolates has steadily increased over time in Asia, Europe, Latin America, the Middle East, North America and the South Pacific.
However only 7 African sites 3.
Although ESBLs producing Enterobacteriaceae are common in hospital acquired Этом LAQ (Easy Gel) 15045 мл Бумажные лепестки, d 4,5 см/3,5 см/2,5 см, упак./25 шт., Астра (розовый) неплохой, they are now being seen in community acquired IAIs as well as.
In 2010, Hawser et al.
The SMART Study data showed a significant increase in ESBL-positive E.
Hospital-acquired isolates were more common than community-acquired isolates, at 14.
Among intra-operative isolates, ESBL producing E.
ESBL producing Enterobacteriaceae were more prevalent in patients with healthcare-associated IAIs than they were in patients with community-acquired IAIs.
Among healthcare associated infections, ESBL-positive E.
Klebsiella pneumoniae Carbapenemases K.
Although carbapenem activity against K.
A total of 2841 clinical isolates of K.
In 2013, Babinchak et al.
The resistance of P.
Imipenem activity remained unchanged with 20 % resistance.
During this period, resistance to piperacillin-tazobactam, cefepime and ceftazidime remained unchanged at 23 to 26 %.
However, the SMART Study demonstrated that the activity of select antimicrobials varied in different regions of the world.
In South Africa during 2004—2009, P.
In China, during relatively the same time period 2002—2009the resistance of P.
In the CIAOW study, among the microorganisms isolated from intraoperative samples, isolates of P.
However, no significant differences between community acquired infections and healthcare associated infections 5.
Enterococci Among Gram-positive bacteria, enterococci play a significant role in IAI.
In 2012 the Dutch Peritonitis Study Group analyzing all patients from the RELAP trial found that the presence of only gram positive cocci, predominantly Enterococcus spp.
This study reported an increase in the prevalence of nosocomial E.
Although enterococci are found in community-acquired infections 11.
Although Enterococci were also present in community-acquired infections, they were more prevalent in healthcare-associated infections 22.
Although community-acquired MRSA has been reported 4 many settings, MRSA has less impact in community-acquired IAI.
However, it should be always considered in the case of wound infections.
MRSA should be suspected in patients with health care—associated IAI known colonized with the organism or who are at risk because of prior treatment failure and significant antibiotic exposure.
The susceptibility pattern differs between community-acquired and hospital acquired MRSA.
In the past, S.
In response, a shift towards the prescription of fluoroquinolones or third-generation cephalosporins has occurred.
In 852 isolates of S.
Resistance to nalidixic acid was found to be highest amongst all the antibiotics; it has been rising since 2005 and is presently 100 %.
Ciprofloxacin resistance was relatively stable over the time period studied with a drastic increase from 5.
Bacteroides fragilis Anaerobes are the predominant components of the bacterial flora of normal human mucous membranes.
Most clinical laboratories do not routinely perform the susceptibility testing of anaerobic isolates.
In fact, their isolation requires appropriate methods of collection, transportation, and cultivation of specimens.
The study analyzed in vitro antimicrobial resistance to both frequently used and newly developed anti-anaerobic agents.
Percent resistance was calculated using breakpoints recommended for the respective antibiotic by the CLSI or Страница States Food and Drug Administration.
These data indicated that the carbapenems imipenem, meropenem, ertapenem, and doripenem and piperacillin-tazobactam were the most active agents against these pathogens, with resistance rates of 0.
Metronidazole and tigecycline were the most active antibiotics among the non-beta-lactam agents.
Metronidazole-resistant Bacteroides strains were also first reported during that period.
Dramatic increases in resistance were observed for cefoxitin, clindamycin and moxifloxacin, with rates of 17.
The lowest resistances were found for imipenem, metronidazole and tigecycline 1.
Antimicrobial stewardship Although most antimicrobial use occurs in the community, the intensity of use in hospitals is far higher; hospitals are therefore particularly important in the containment of antimicrobial resistance.
Hospital based Antibiotic Stewardship Programs ASPs can help clinicians both to optimize the treatment of infections and reduce adverse events associated with antibiotic use.
Given the urgent need to improve antimicrobial use in healthcare all acute care hospitals should implement Antibiotic Stewardship Programs.
Antimicrobial stewardship is an emerging strategy designed to optimize outcomes and reduce the emergence of resistant organisms through the pillars of surveillance, infection control and optimizing the use of antimicrobial therapy.
Core principles of antimicrobial stewardship include the use of antibiotic prophylaxis only when there is proven efficacy, use of the narrowest spectrum of antimicrobial therapy with proven efficacy, use of the least number of agents and for the shortest length of therapy to achieve efficacy, and appropriate antimicrobial dosing to maximize efficacy and limit complications.
Observational data support a significant association мне Костюм Дед Мороз Chic a Loco вам stewardship practices and reduction of antibiotic resistance.
In a retrospective before and after study design, analysis of two ICUs within a single institution trauma and surgical before and after the implementation of service specific antibiotic stewardship protocols, Dortch et al.
Restriction of antimicrobial use may be obtained either by limited access to available antimicrobials in the hospital through restriction of the hospital formulary, or implementation of a requirement for preapproval and a justification for prescribing drugs on the restricted list.
To estimate the effectiveness of antimicrobial stewardship programs and evaluate their impact on the incidence of antimicrobial-resistant pathogens or C.
Eighty-nine studies were included.
The meta-analysis showed that interventions to decrease excessive antibiotic prescribing for hospital inpatients reduced antimicrobial resistance and hospital-acquired infections.
Interventions to increase effective prescribing improved clinical outcomes.
These data supported the use of restrictive interventions in urgent cases.
However, persuasive and restrictive interventions were equally effective after six months.
Restrictive interventions do seem to have a greater immediate impact than persuasive interventions.
Prescribing is a complex social process.
Restriction is useful in urgent situations, but because of the reduced effects over time, programs and strategies should be balanced with positive actions.
The ultimate goal of a stewardship should be to stimulate a behavioral change in prescribing practice.
In this context, education of prescribers is crucial to convince clinicians to use antibiotics judiciously.
The supplemental strategies employed in ASP include, implementation of guidelines and clinical pathways, antimicrobial order forms, streamlining or de-escalation, combination therapy, dose optimization, and IV-to-PO switch, therapeutic substitution, cycling, mixing and use of computer decision support.
In general, больше на странице of these strategies are implemented in the daily practice simultaneously with one or both of the two core strategies.
Management of intra-abdominal infections The treatment of patients with complicated IAI involves both timely source control and antimicrobial therapy.
Empiric antimicrobial therapy is important in the management of intra-abdominal infections and must be broad enough to cover all likely organisms.
Adequate source control is mandatory in the management of complicated IAIs.
The treatment of patients with complicated IAI involves both source control and antimicrobial therapy.
Surgical source control entails resection or suture of a diseased or perforated viscus e.
The source control procedure will depend on the patient characteristics, organ affected, and specifically on the pathology that is encountered.
Although new surgical techniques, supported by innovative technology, have improved treatment for these patients, the markedly reduced development of new antibiotics has been unable to match the rapidly increasing phenomena of antimicrobial resistance making it a major ongoing challenge associated with the management of complicated IAI.
Antimicrobial therapy plays an integral role in the management of complicated IAI.
The main objectives of antimicrobial therapy in the treatment of IAI are to prevent local and haematogenous spread, and to reduce late complications.
Classifications The term intra-abdominal infections IAIdescribes a wide heterogeneity of patient populations.
A complete classification that includes all aspects of intra-abdominal infections does not exist.
IAI encompass a variety of pathological conditions, ranging from uncomplicated appendicitis to faecal peritonitis.
In uncomplicated IAI, the infection only involves a single organ and does not extend to the peritoneum.
These situations require both source control and antimicrobial therapy.
Primary peritonitis is a diffuse bacterial infection usually single organism without loss of integrity of the gastrointestinal tract, typically seen in cirrhotic patients with ascites or patients with an indwelling peritoneal 4 catheter.
Examples include visceral perforations or necrosis of the gastrointestinal tract, blunt or penetrating trauma, and post-operative leakage of anastomoses or suture lines.
It is more common among critically ill or immunocompromised patients and may often be associated with highly resistant pathogens including candida spp.
It is typically associated with high morbidity and mortality.
Hospital-acquired intra-abdominal infections HA-IAI are often associated with surgery or another invasive procedure gastrointestinal endoscopy, invasive radiology.
However, in the years after the first proposal by Friedman et al.
Differentiating community-acquired intra-abdominal infection CA-IAIs and healthcare-associated intra-abdominal infections HCA-IAIs is useful to define the presumed resistance patterns and specify patients with increased likelihood of infection caused by MDRO.
Among patients with HCAI, those with hospital-acquired infections may be associated with increased mortality due to underlying patient health status and severity criteria at the time of diagnosis.
Grading of the clinical severity of patients with complicated IAI has been be well described by the sepsis definitions.
The overall mortality rate was 10.
Recently, sepsis definitions were revised.
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
Antimicrobials should be used after a treatable IAI has been recognized or when there is a high degree of suspicion for infection.
Every clinician starting empiric therapy should know the local epidemiology.
Surveillance initiatives are important, both in a local and in a global context.
If local epidemiology suggests that a patient has been infected with a strain already known to be resistant to antibiotics, then inappropriate antimicrobial therapy, which fails to cover known resistance patterns risks further disruption of the natural flora and selecting for resistant variants without providing effective treatment.
Published guidelines Different sets of guidelines for the management of patients with IAIs have been published.
Guidelines have a great impact on clinical care.
They should incorporate stewardship principles.
Historically, treatment guidelines have not taken into consideration antimicrobial stewardship principles when setting the priority order of antimicrobial options, and instead have focused primarily on safety and efficacy data.
Guidelines have major impact on delivery of clinical care, and on regulatory review of hospital performance.
Hopefully, these guidelines will evolve to incorporate stewardship principles, in addition to safety and efficacy, when setting the priority order for recommended antimicrobial therapies.
Antimicrobial selection in community-acquired infections For patients with CA-IAI, antimicrobial agents with a narrow spectrum of activity encompassing all likely organisms should be administered.
However, a patient with risk factors for ESBL infection who is hemodynamically unstable may warrant empiric therapy to cover for ESBLs, with plans to de-escalate therapy once microbiology is known.
Therefore, they are predictable and include Enterobacteriaceae predominantly E.
For patients with CA-IAI, antimicrobial agents with a relatively narrower spectrum of activity encompassing wild-type strains from the above-mentioned species should be administered.
However, if patients with CA-IAI have risk factors for infections due to ESBL producing Enterobacteriaceae, and in particular if the patient is hemodynamically unstable, antimicrobial agents that are effective against ESBLs may be warranted.
In contrast, less severely ill patients may have more time for the clinician to know that initial therapy was not active.
Antimicrobial selection in health-care associated infections For patients with HCA-IAI, empiric antimicrobial regimens with broader spectra of activity should be administered as these patients have a higher risk of infections due to MDRO.
On receiving results of susceptibility testing, the clinician should opt for a narrow spectrum antimicrobial agent, which covers the likely causative organism.
Antibiotic selection in critically Ill patients An inadequate empiric antimicrobial regimen is associated with unfavorable outcomes in critical ill patients.
Abdominal sepsis is a common indication for admission to the ICU.
Disease severity, need for organ support, and presence of co-morbidities were independently associated with mortality.
Antibiotic armamentarium The choice of empiric antibiotics in patients with IAI should be based on the severity of the infection, the individual risk for infection by resistant pathogens, and the local resistance epidemiology.
The use of carbapenems should be limited so as to preserve activity of this class of antibiotics because of the concern of emerging carbapenem-resistance.
Ciprofloxacin and levofloxacin are no longer appropriate first-line choices for empiric treatment in many regions because of the prevalence of fluoroquinolone resistance.
Other options include aminoglycosides, particularly for suspected infections by Gram negative bacteria, and tigecycline especially when MDRO are suspected, though caution is advised for the latter, in the situation of a bacteremia.
IAI may be managed by either Настольные часы Rhythm CRH261NR06 отцу or multiple antimicrobial regimens.
Table presents the spectrum of activity of antimicrobial agents for common Https://realgost.ru/panel/maslo-transmissionnoe-g-box-atf-dx-vi-1-l.html pathogens, Table presents recommended intravenous antimicrobial doses for patients with IAI and preserved renal function.
Antibiotics for treating patients with intra-abdominal infections based upon susceptibility.
This is likely due to excessive use of amoxicillin and amoxicillin-clavulanate in both children and adults, particularly in the treatment of upper respiratory tract infection.
The combination of over use of these oral antibiotics in the community and potential for household transmission of resistant E.
The study reported no statistically significant difference in mortality between carbapenems and BLBLI administered as either empiric or definitive therapy.
Cephalosporins Most isolates of E.
Among this drug class, cefotaxime, ceftriaxone and ceftizoxime, in combination with metronidazole may be options for empirical therapy of CA-IAI, due to the relatively narrow spectrum of coverage bacause these agents lack activity against P.
On the other hand, ceftazidime and cefoperazone have activity against P.
Their role towards E.
It has not been approved for the treatment of cIAI.
Ciprofloxacin has in vitro activity against P.
Ciprofloxacin has lowest MIC against P.
Except for moxifloxacin, the FQ have a moderate activity against anaerobes and have been used in combination with metronidazole in the empiric treatment of IAI.
FQ are rapidly, and almost completely, absorbed from the gastrointestinal tract, particularly levofloxacin and moxifloxacin.
Therefore, the empiric use of FQ for IAI is discouraged in patients with recent exposure to this class of antibiotics.
In addition, the increasing use of FQ in aged care facilities, particularly for the treatment of urinary tract infections, has contributed to the emergence of E.
In recent years, resistance of E.
The worldwide increase in FQ resistance among E.
Carbapenems For decades, carbapenems have been the antibiotics of first choice for ESBLs.
The best option for targeting ESBLs though with no coverage of P.
In addition, carbapenems are not generally recommended for use to treat bacteremia due to Enterococcus spp.
In carbapenemase producing K.
Aminoglycosides Aminoglycosides are particularly active against aerobic Gram-negative bacteria and act synergistically against certain Gram-positive organisms.
They are effective against P.
Because of their serious toxic side effects including nephrotoxicity and ototoxicity, some authors do not recommend aminoglycosides for the routine empiric treatment of community-acquired IAI.
Tigecycline Tigecycline, an antibiotic from the group of the tetracyclines, does not feature in vitro activity against P.
Study-level and patient-level analyses identified that patients in the hospital-acquired pneumonia trial, particularly those with ventilator-associated pneumonia with baseline bacteremia, were at a higher risk of clinical failure and mortality.
A mortality analysis was ссылка на страницу to investigate the association of baseline factors in abdominal infections, including severity of illness at study entry and treatment assignment, with clinical failure and mortality.
Mortality modelling identified multiple factors associated with death which did not include tigecycline and which were forced into the model.
Similarly, attributable mortality, among subjects who died of primary infection, in the cIAI studies, showed no difference among treatments.
Because of poor plasma concentration tigecycline performs poorly in bacteremic patients, with a much higher risk of failing clear bacteremia than the comparator.
Tigecycline should not be considered first line for health care associated pneumonia, bacteremia or endocarditis.
Polymixins Polymyxins, discovered in 1940s, are a group of polycationic peptide antibiotics that exhibit potent efficacy against most gram-negative bacteria.
Among all the five chemical compounds A—E of polymyxins, only polymyxin B and E colistin are clinically used.
Since the 1970s, these preparations were practically abandoned because of reports of severe adverse events.
The nephrotoxicity and neurotoxicity of polymyxins has been the major limiting factor in their clinical application.
The EMA recommendations were based on a review of the available Индукционная варочная панель HI 641, pharmacological and pharmacokinetic data.
EMA recommended expression of colistin dose in IU of colistimethate sodium.
Based on the limited available evidence the recommended dose in adults was 9 million IU approximately 300 mg daily in 2 or 3 divided doses as a slow intravenous infusion; in critically ill patients a loading dose of 9 million IU was suggested.
EMA suggested to reduce dosage according to creatinine clearance in patients with renal impairment.
Also US Food and Drug Administration FDA approved changes to the dosage and administration section of the product label for colistimethate in the United States.
The recommended dose was 2.
A loading dose was not recommended for critically ill patients.
The FDA recommended dosing regimen accounts for renal function.
While traditionally fosfomycin disodium was administered parenterally, several countries have recently approved the oral administration of fosfomycin tromethamine for treating urinary tract infections UTIs caused by Escherichia coli and E.
Its use as a single agent is usually restricted in critically ill patients.
The daily dose of intravenous fosfomycin disodium ranges from 12 to 16 g on average, administered in 2—4 infusions.
Renal impairment significantly decreases the excretion of fosfomycin.
By adding beta-lactamase inhibitor tazobactam or avibactamthese new agents have strong activity against MDR Gram-negative pathogens.
Unlike other beta-lactam and beta-lactamase inhibitor combination agents, these new agents should be combined with metronidazole for complicated IAI due to limited activity against some Bacteroides species.
These antibiotics will be valuable for treating infections caused by MDR Gram-negative bacteria in order to preserve carbapenems.
Cautious clinical use is advised, until their precise roles are further defined as empirical treatment.
The epidemiological role of Candida spp.
However, recent data suggest that some specific subpopulations are at higher risk of fungal involvement, i.
In a recent study, Zappella et al.
Isolation of Candida spp.
In an observational study, Montravers et al.
Clinical evidence supporting the use of antifungal therapy for patients with suspected intra-abdominal invasive candidiasis is limited.
Most studies are small and uncontrolled, single-center, or performed in specific patient cohorts.
IDSA guidelines suggested considering empiric antifungal therapy for patients with clinical evidence of intra-abdominal infection and significant risk factors for candidiasis, including those with recent abdominal surgery, anastomotic leaks, or necrotizing pancreatitis, who are doing poorly despite treatment for https://realgost.ru/panel/stenovie-paneli-cnf168-korichneviy-kamen.html infections.
The study was unable to provide evidence that preemptive administration of an echinocandin was effective in preventing IC in high-risk surgical intensive care unit patients with intra-abdominal infections.
Preferred empiric therapy in critically ill patients or those previously exposed to an azole is an echinocandin caspofungin: loading dose of 70 mg, then 50 mg daily; micafungin:100 mg daily; anidulafungin: loading dose of 200 mg, then 100 mg daily.
The duration of therapy should be determined by adequacy of source control and clinical response.
Dosage Knowledge of the pharmacokinetic and pharmacodynamic antimicrobial properties of each antimicrobial inform rational dosing.
The antimicrobial dosing regimen should be established depending on host factors and properties of antimicrobial agents.
Antimicrobial pharmacodynamics integrates the complex relationship between organism susceptibility and patient pharmacokinetics.
Pharmacokinetics describes the fundamental processes of absorption, distribution, metabolism, and elimination and the resulting concentration-versus-time profile of an agent administered in vivo.
The achievement of appropriate target site concentrations of antimicrobials is essential to eradicate the relevant pathogen.
Antimicrobials typically need to reach a site of action outside the plasma.
This requires the drug to pass through the capillary membranes.
Commonly encountered situations where pharmacokinetics change and dosing individualization may be necessary include renal and hepatic dysfunction.
Dose reductions may be necessary to prevent accumulation and toxicity in patients with reduced renal or hepatic function.
Dosing frequency is related to the concept of time-dependent versus concentration-dependent killing.
Therefore, it is important that the serum concentration exceeds the MIC for appropriate duration of the dosing interval for the antimicrobial and the organism.
For beta lactams, prolonged or continuous infusions have been advocated in order to maximize the time that the drug concentration exceeds the MIC, whereas high peak concentrations are not beneficial.
These results may not be generalizable to patients with high severity of illness and infections caused by less susceptible pathogens with high MIC e.
Prolonged or continuous infusions of beta lactams should therefore be considered for the treatment of critically ill patients with hospital-acquired IAI.
In contrast, antibiotics such as aminoglycosides exhibit concentration-dependent activity and should be administered in a once daily manner or with the least possible number of daily administrations in order to achieve high peak plasma concentrations.
In terms of toxicity, aminoglycosides nephrotoxicity is caused by a direct effect on the renal cortex and its uptake saturation.
This optimal first dose could be described as a loading, or front-loaded dose and is calculated from the volume of distribution Vd of the drug and the desired plasma concentration.
The Vd of hydrophilic agents which disperse mainly in water such as beta-lactams, aminoglycosides and glycopeptides in patients with septic shock may be altered by changes in the permeability of the microvascular endothelium and consequent alterations in extracellular body water.
When drains have been inserted, large drainage volume outputs may also affect antibiotic concentration, and may need to be accounted for when considering dosage and frequency of administration.
Once an appropriate initial loading dose is achieved, the antimicrobial regimen should be reassessed, at least daily, because pathophysiological changes may significantly affect drug availability in the critically ill patients.
It should be noted that in critically ill patients, plasma creatinine is an unreliable marker of renal function.
They should be always performed in patients with healthcare-associated infections or with community-acquired infections at risk for resistant pathogens.
When a microorganism is identified in clinical cultures, antimicrobial susceptibility testing AST should always be performed and reported to guide antibiotic therapy.
However, this observation may not address the issues surrounding the threats of antibiotic resistance.
The results of microbiological testing may have great importance for the choice of therapeutic strategy of every patient, in particular in the adaptation of targeted antimicrobial treatment.
While the yield of blood cultures may be relatively low in patients with IAI, clinicians should not miss an easy opportunity to establish the microbiologic etiology by obtaining two sets of blood cultures prior to starting antibiotics, particularly in patients admitted to the hospital in critically ill conditions.
Sufficient fluid volume usually at least 1 mL of fluid or tissue must be collected, and then transported to the microbiology laboratory using a transport system that properly handles and preserves the samples to avoid damage or compromise their integrity.
When a microorganism is identified in clinical cultures, antimicrobial susceptibility testing AST should always be performed and reported to guide antibiotic therapy.
AST measures the ability of a specific organism to grow in the presence of a particular drug using guidelines established by either the Clinical or Laboratory Standards Institute CLSI in United States or the European Committee for Antimicrobial Susceptibility Testing EUCAST in Europe.
In vitro susceptibility results are correlated with the clinical success or failure of an antibiotic against a particular organism.
Data are reported in the form of MIC, which is the lowest concentration of an antibiotic that inhibits visible growth of a microorganism.
In general, it may be a wise practice to communicate directly with the microbiology laboratory when antimicrobial susceptibility patterns appear unusual.
Antimicrobial duration In patients with uncomplicated IAI, and where the source of infection is treated definitively, post-operative antimicrobial therapy is not necessary.
In patients with complicated IAI undergoing an adequate source-control procedure, post-operative therapy should be shortened as much as possible after the resolution of physiological abnormalities.
In the event of uncomplicated IAIs, the infection involves a single organ and does not extend to the peritoneum.
Treatment of patients with complicated IAI generally involves both source control and antimicrobial therapy.
Antibiotics to treat IAI with antimicrobials can prevent local and hematogenous spread and may reduce late complications.
The optimal duration of antibiotic therapy for cIAIs is debated.
The recent prospective trial by Sawyer et al.
Duration of therapy больше на странице be shortened as much as possible unless there are special circumstances that require prolonging antimicrobial therapy such as immunosuppression, or ongoing infections.
Oral antimicrobials, can substitute IV agents as soon as the patient is tolerating an oral diet so as to minimize the adverse effects which are associated with intravenous access devices.
Where possible, conversion to oral antimicrobial agents having high oral bioavailability e.
Patients who have signs of sepsis beyond 5 to 7 days of treatment warrant aggressive diagnostic investigation to determine if an ongoing uncontrolled source of infection or antimicrobial treatment failure is present.
Conclusions An optimal antimicrobial approach to treating IAI involves a delicate balance between the optimization of empiric therapy, which improves clinical outcomes, and the reduction of excessive antimicrobial use, which increases the rate of emergence of antimicrobial-resistant strains.
Increasing resistance rates among Gram-negative pathogens that are responsible for serious nosocomial infections, including ESBL Enterobacteriaceae, MDR P.
These organisms represent an emerging threat due to the limited availability of viable therapeutic options.
This complicates the choice of the most appropriate empiric treatment for patients with IAI.
The clinical challenge remains to find the balance between ensuring that each individual patient is appropriately covered for the most likely pathogens of their IAI, while avoiding the use of overtly broad-spectrum antimicrobials in order to preserve them for future use.
The appropriateness and need for antimicrobial treatment should be re-assessed daily.
Treatment duration as short as 4 days may be sufficient for a vast majority of patients suffering from complicated IAIs, when coupled with effective source control.
Although most clinicians are aware of the problem of antimicrobial resistance, most underestimate its importance; judicious antimicrobial management decisions is an integral part of responsible medication prescribing behavior.
In recommendations for appropriate therapy in patients with intra-abdominal infections are reported.
Abbreviations AMR, antimicrobial resistance; IAIs, intra-abdominal infections; CDI, C.
All authors reviewed and approved the final manuscript.
The views expressed in this article are those of ссылка на страницу authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.
Contributor Information Massimo Sartelli, Email:Email:.
Abdulrashid Kayode Adesunkanmi, Email:.
Asri Che Jusoh, Email:.
Belinda De Simone, Email:.
Salomone Di Saverio, Email:.
Mushira Abdulaziz Enani, Email:.
Carlos Augusto Gomes, Email:.
Jae Gil Lee, Email:.
Young Ran Lee, Email:.
Renato Bessa Melo, Email:.
Carl Erik Nord, Email:.
Gerson Alves Pereira Júnior, Email:.
Timothy Miles Rawson, Email:.
Ngo Tat Trung, Email:.
Harry van Goor, Email:.
Dellit TH, Owens RC, McGowan JE, Jr, Gerding DN, Weinstein RA, Burke JP, et al.
Infectious Diseases Society of America.
Society for Healthcare Epidemiology of America Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al.
Bad bugs, no drugs: no ESKAPE!
An update from the Infectious Diseases Society of America.
Risk factors for the spread of antibiotic-resistant bacteria.
Deege MP, Paterson DL.
Reducing the development of antibiotic resistance in critical care units.
Septimus EJ, Owens RC.
Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee HICPAC.
Am J Infect Control.
Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli.
Salyers AA, Gupta A, Wang Y.
Human intestinal bacteria as reservoirs for antibiotic resistance genes.
Vollaard EJ, Clasener HA.
Bhalla A, Pultz NJ, Ray AJ, Hoyen CK, Eckstein EC, Donskey CJ.
Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients.
Infect Control Hosp Epidemiol.
Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al.
Effect of antibiotic therapy on the density of vancomycin-resistant жмите in the stool of colonized patients.
N Engl J Med.
Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al.
Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ruppé E, Lixandru B, Cojocaru R, Büke C, Paramythiotou E, Angebault C, et al.
Relative fecal abundance of extended-spectrum-beta-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women.
Antimicrobial resistance: action to combat the rising microbial challenges.
Int J Antimicrob Agents.
Pulcini C, Gyssens IC.
How to educate prescribers in antimicrobial stewardship practices.
Viscidi R, Willey S, Bartlett JG.
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.
Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, et al.
WSES guidelines for management of Clostridium difficile infection in surgical patients.
World J Emerg Surg.
Farrell RJ, LaMont JT.
Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis.
Curr Top Microbiol Immunol.
Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ.
Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics.
Muto CA, Pokrywka M, Shutt K, Mendelshon AB, Nouri K, Posey K, et al.
A large outbreak of Clostridium difficile—associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.
Infect Control Hosp Epidemiol.
Loo VG, Poirier L, Miller MA, Oughton M, Libman MB, Michaud S, et al.
A predominately clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
N Engl J Med.
Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al.
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
Dubberke ER, Reske Смотрите подробнее, Yan Y, Olsen MA, McDonald LC, Fraser VJ.
Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors.
Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA.
Antimicrobial-associated risk factors for Clostridium difficile infection.
McCusker ME, Harris AD, Perencevich E, Roghmann M.
Fluoroquinolone use and Clostridium difficile-associated diarrhea.
Leffler DA, Lamont JT.
N Engl J Med.
Slimings C, Riley TV.
Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis.
Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, et al.
Intracolonic vancomycin for severe Clostridium difficile colitis.
Surg Infect Larchmt 2013; 14:532—539.
Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS.
Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostrodium difficile associated disease.
Bougnoux ME, Diogo D, François N, Sendid B, Veirmeire S, Colombel JF, et al.
Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract.
Kam AP, Xu J.
Diversity of commensal yeasts within and among healthy hosts.
Diagn Microbiol Infect Dis.
Xu J, Boyd CM, Livingston E, Meyer W, Madden JF, Mitchell TG.
Species and genotypic diversities and similarities of pathogenic yeasts colonizing women.
Miranda LN, Van Der Heijden IM, Costa SF, Sousa AP, Sienra RA, Gobara S, et подробнее на этой странице />Candida colonisation as a source for candidaemia.
Yan L, Yang C, Tang J.
Disruption of the intestinal mucosal barrier in Candida albicans infections.
Schulte DM, Sethi A, Gangnon R, Duster M, Maki DG, Safdar N.
Risk factors for Candida colonization and Co-colonization with multi-drug resistant organisms at admission.
Antimicrob Resist Infect Control.
Aly M, Balkhy HH.
The prevalence of antimicrobial resistance нажмите для деталей clinical isolates from gulf corporation council countries.
Antimicrob Resist Infect Lucius The life of the Hon.
Sir Charles W.
Dilke, Bart., />Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al.
Antibiotic resistance-the need for global solutions.
Ashiru-Oredope D, Cookson B, Fry C, Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection Professional Education Subgroup Developing the first national antimicrobial prescribing and stewardship competences.
Allegranzi B, Pittet D.
Preventing infections acquired during health-care delivery.
Antimicrobial resistance and healthcare-associated infections.
Accessed 03 Apr 2016.
World Health Organization WHO.
Global action plan on antimicrobial resistance.
Accessed 03 Apr 2016.
Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens Кувалда JCB JHM010 ти, Holmes A, et al.
Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum.
Antimicrob Resist Infect Control.
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al.
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study.
Pitout JD, Laupland KB.
Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.
Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams.
Infect Dis Clin North Am.
Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, et al.
Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features.
Thaden JT, Fowler VG, Sexton DJ, Anderson DJ.
Increasing Incidence of Узнать больше beta-lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States.
Infect Control Hosp Epidemiol.
Makoka MH, Miller WC, Hoffman IF, Cholera R, Gilligan PH, Kamwendo D, et al.
Bacterial infections in Lilongwe, Malawi: aetiology and antibiotic resistance.
Mechanisms of bacterial resistance to antimicrobial agents.
Am J Health Syst Pharm.
Martinez JL, Baquero F.
Mutation frequencies and antibiotic resistance.
Palmer KL, Kos VN, Gilmore MS.
Horizontal gene transfer and the genomics of enterococcal antibiotic resistance.
Billard-Pomares T, Fouteau S, Jacquet ME, Roche D, Barbe V, Castellanos M, et al.
Characterization of a P1-like bacteriophage carrying an SHV-2 extended-spectrum β-lactamase from an Escherichia coli strain.
Brown-Jaque M, Calero-Cáceres W, Muniesa M.
Transfer of antibiotic-resistance genes via phage-related mobile elements.
Why does Evolution Matter?
The Importance of Understanding Evolution.
UK: Cambridge Scholars Publishing; 2014.
Chapter Ten: The forces behind the dissemination of bacterial virulence and antibiotic resistance.
Iida S, Meyer J, Arber W.
Genesis and natural history of IS-mediated transposons.
Cold Spring Harb Symp Quant Biol.
Poirel L, Marqué S, Héritier C, Segonds C, Chabanon G, Nordmann P.
OXA-58, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumannii.
Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R, Philippon A.
Beta-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types.
Ray MD, Boundy S, Archer GL.
Transfer of the methicillin resistance genomic island among staphylococci by conjugation.
Chen L, Mathema B, Pitout JD, DeLeo FR, Kreiswirth BN.
Epidemic Klebsiella pneumoniae ST258 is a hybrid strain.
Smyth DS, McDougal LK, Gran FW, Manoharan A, Enright MC, Song JH, et al.
Population structure of a hybrid clonal group of methicillin-resistant Staphylococcus aureus, ST239-MRSA-III.
Bush K, Fisher JF.
Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from Gram-negative bacteria.
The structure of beta-lactamases.
Philos Trans R Soc Lond B Biol Sci.
Bush K, Jacoby GA, Перейти AA.
A functional classification scheme for beta-lactamases and its correlation with molecular structure.
Bush K, Jacoby GA.
Updated Functional Classification of beta-Lactamases.
Ruppé É, Woerther PL, Barbier F.
Mechanisms of antimicrobial resistance in Gram-negative bacilli.
Kang CI, Pai H, Kim SH, Kim HB, Kim EC, Oh MD, et al.
Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediatedAmpC-type beta-lactamase.
Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, et al.
The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae.
Schultsz C, Geerlings S.
Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy.
Global fluoroquinolone resistance epidemiology and implictions for clinical use.
Interdiscip Perspect Infect Dis.
Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective.
Perez F, Bonomo RA.
Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al.
DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?
Paterson D, Bonomo R.
Woerther PL, Burdet C, Chachaty E, Andremont A.
Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M.
Weldhagen GF, Poirel L, Nordmann P.
Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact.
Beta-lactamases in laboratory and clinical resistance.
Hammoudi D, Ayoub Moubareck C, Aires J, Adaime A, Barakat A, Fayad N, et al.
Countrywide spread of OXA-48 carbapenemase in Lebanon: surveillance and genetic characterization of carbapenem-non-susceptible Enterobacteriaceae in 10 hospitals over a one-year period.
Int J Infect Dis.
Poirel L, Héritier C, Tolün V, Nordmann P.
Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae.
Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG.
Decreased susceptibility to polymyxin B during treatment of carbapenem-resistant Klebsiella pneumoniae infection.
Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al.
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.
Ducomble T, Faucheux S, Helbig U, Kaisers UX, König B, Knaust A, et al.
Large hospital outbreak of KPC-2-producing Klebsiella pneumoniae: investigating mortality and the impact of screening for KPC-2 with polymerase chain reaction.
Lübbert C, Lippmann N, Busch T, Kaisers UX, Ducomble T, Eckmanns T, et al.
Long-term carriage of Klebsiella pneumoniae carbapenemase-2-producing K pneumoniae after a large single-center outbreak in Germany.
Am J Infect Control.
Lübbert C, Rodloff AC, Больше на странице S, Simon P, Busch T, Mössner J, et al.
Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2-producing K.
Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL.
Treating infections caused by carbapenemase-producing Enterobacteriaceae.
Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al.
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.
Metallo-beta-lactamase structure and function.
Ann N Y Acad Sci.
Cornaglia G, Giamarellou H, Rossolini GM.
Metallo-beta-lactamases a last frontier for beta-lactams?
Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al.
Characterization of a new metallo-beta-lactamase gene, bla NDM-1and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
Brink AJ, Coetzee J, Clay CG, Sithole S, Richards GA, Poirel L, et al.
Emergence of New Delhi Metallo-Beta-Lactamase NDM-1 and Klebsiella pneumoniae Carbapenemase KPC-2 in South Africa.
Fàbrega A, Madurga S, Giralt E, Vila J.
Mechanism of action of and resistance to quinolones.
Mechanisms of resistance to quinolones.
Ramirez MS, Tolmasky ME.
Kumari H, Balasubramanian D, Zincke D, Mathee K.
Role of Pseudomonas aeruginosa AmpR on beta-lactam and non-beta-lactam transient cross-resistance 4 pre-exposure to subinhibitory concentrations of antibiotics.
Lister PD, Gardner VM, Sanders CC.
Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.
Efflux-mediated multiresistance in Gram-negative bacteria.
Venter H, Mowla R, Ohene-Agyei T, Ma S.
RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition.
Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM.
Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.
Int J Med Microbiol.
Manchanda V, Sanchaita S, Singh N.
J Glob Infect Dis.
Potron A, Poirel L, Nordmann P.
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology.
Int J Antimicrob Agents.
Optimizing therapy for vancomycin-resistant Enterococci VRE Semin Respir Crit Care Med.
Chou YY, Lin TY, Lin JC, Wang NC, Peng MY, Chang FY.
Vancomycin-resistant enterococcal bacteremia: Comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis.
J Microbiol Immunol Infect.
Hollenbeck BL, Rice LB.
Intrinsic and acquired resistance mechanisms in enterococcus.
Hodges TL, Zighelboim-Daum S, Eliopoulos GM, Wennersten C, Moellering RC.
Marothi YA, Agnihotri H, Dubey D.
Indian J Med Microbiol.
Mahbub Alam M, Kobayashi N, Ishino M, Sumi A, Kobayashi K, Uehara N, et al.
Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P.
Modes and modulations of antibiotic resistance gene expression.
Vancomycin-resistant Enterococci: Clinical, microbiologic, and epidemiologic features.
J Lab Clin Med.
Fang H, Edlund C, Hedberg M, Nord CE.
New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group.
Int J Antimicrob Agents.
Rasmussen BA, Bush K, Tally FP.
Antimicrobial resistance in anaerobes.
Gutacker M, Valsangiacomo C, Piffaretti JC.
Identification of two genetic groups in Bacteroides fragilis by multilocus enzyme electrophoresis: distribution of antibiotic resistance cfiA, cepA and enterotoxin bft encoding genes.
Ang L, Brenwald NP, Walker RM, Andrews J, Fraise A.
Carbapenem resistance in Bacteroides fragilis.
Ingham HR, Eaton S, Venables CW, Adams PC.
Bacteroides fragilis resistant to metronidazole after long-term therapy.
Diniz CG, Farias LM, Carvalho MA, Rocha ER, Smith CJ.
Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant.
Pumbwe L, Chang A, Smith RL, Wexler HM.
BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis.
Nagy E, Urbán E, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience.
Sartelli M, Catena F, Di Saverio S, Ansaloni L, Coccolini F, Tranà C, et al.
The Challenge of antimicrobial resistance in managing intra-abdominal infections.
Surg Infect Larchmt 2015; 16:213—220.
Morrissey I, Hackel Нажмите для деталей, Badal R, Bouchillon S, Hawser S, Biedenbach D.
A review of ten years of the study for monitoring antimicrobial resistance trends SMART from 2002 to 2011.
Pharmaceuticals Basel 2013; 6:1335—1346.
Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Cantón R, Baquero F.
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrobial Resistance Trends SMART Antimicrob Agents Chemother.
Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, 4 al.
Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study.
World J Emerg Surg.
Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, et al.
Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates.
Babinchak T, Badal R, Hoban D, Hackel M, Hawser S, Lob S, et al.
Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005—2010.
Diagn Microbiol Infect Dis.
Sitges-Serra A, Lopez MJ, Girvent M, Almirall S, Sancho JJ.
Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis.
Burnett RJ, Haverstock DC, Dellinger EP, Reinhart HH, Bohnen JM, Rotstein OD, et al.
Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial.
Dupont H, Friggeri A, Touzeau J, Airapetian N, Tinturier F, Lobjoie E, et al.
Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit.
Kaffarnik MF, Urban M, Hopt UT, Utzolino S.
Impact of enterococcus on immunocompetent and immunosuppressed patients with perforation of the small or large bowel.
Van Ruler O, Kiewiet JJ, Van Ketel RJ, Boermeester MA, Dutch Peritonitis Study Group Initial microbial spectrum in severe secondary peritonitis and relevance for treatment.
Eur J Clin Microbiol Infect Бей Кассетный кондиционер Hisense AUC-24UX4SEA 4 />Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al.
Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study.
Verma H, Pandey S, Sheoran KD, Marwah S.
Surgical audit of patients with ileal perforations requiring ileostomy in a Tertiary Care Hospital in India.
Mirza SH, Beeching NJ, Hart CA.
Multi-drug resistant typhoid: a global problem.
Hammad OM, Abdel Wahab MF, Zaky S, Abdel Baki AM, Afify A, El Tantawi MA.
Multidrug resistant typhoid fever in Egypt.
J Med Lab Sci.
Singhal L, Gupta PK, Kale P, Gautam V, Ray P.
Trends in antimicrobial susceptibility of Salmonella typhi from North India 2001—2012 Indian J Med Microbiol.
Brook I, Wexler HM, Goldstein EJ.
Antianaerobic antimicrobials: spectrum and susceptibility testing.
Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al.
Lessons learned from the anaerobe survey: historical perspective and review of the most recent data 2005—2007 Clin Infect Dis.
Ramsay C, Brown E, Hartman G, Davey P.
Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing.
Dortch MJ, Fleming SB, Kauffmann RM, Dossett LA, Talbot TR, May AK.
Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections.
Surg Infect Larchmt 2011; 12:15—25.
White AC, Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB.
Effects of requiring prior authorization for selected antimicrobials: 4, susceptibilities, and clinical outcomes.
Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al.
Interventions to improve antibiotic prescribing practices for hospital inpatients.
Cochrane Database Syst Rev.
Principles of source control 4 the early management of sepsis.
Curr Infect Dis Rep.
Wacha H, Hau T, Dittmer R, Ohmann C.
Risk factors associated with intraabdominal infections: a prospective multicenter study.
Sartelli M, Abu-Zidan FM, Catena F, Griffiths EA, Di Saverio S, Coimbra R, et al.
Global validation of the WSES Sepsis Severity Score for patients with complicated intra-abdominal infections: a prospective multicentre study WISS Study World J Emerg Surg.
VanSonnenberg E, Ferrucci JT, Mueller PR, Wittenberg J, Simeone JF.
Percutaneous drainage of abscesses and fluid collections: Technique, results, and applications.
Bouali K, Magotteaux P, Jadot 4, Saive C, Lombard R, Weerts J, et al.
Percutaneous catheter drainage of abdominal abscess after abdominal surgery: Results in 121 cases.
VanSonnenberg E, Wing VW, Casola G, Coons HG, Nakamoto SK, Mueller PR, et al.
Temporizing effect of percutaneous drainage of complicated abscesses in critically ill patients.
Jaffe TA, Nelson RC, DeLong D, Paulson EK.
Practice Patterns in Percutaneous Image-guided Intra-abdominal Abscess Drainage: Survey of Academic and Private Practice Centres.
Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, et al.
Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome.
Kirkpatrick AW, Roberts DJ, Faris PD, Ball CG, Kubes P, Tiruta C, et al.
Active Negative Pressure Peritoneal Therapy After Abbreviated Laparotomy: The Intraperitoneal Vacuum Randomized Controlled Trial.
Menichetti F, Sganga G.
Definition and classification of intra-abdominal infections.
A focus on intra-abdominal infections.
World J Emerg Surg.
Gupta S, Kaushik R.
World J Emerg Surg.
Mishra SP, Tiwary SK, Mishra M, Gupta SK.
An introduction of Tertiary Peritonitis.
J Emerg Trauma Shock.
Reemst PH, 4 Goor H, Goris RJ.
SIRS, MODS and tertiary peritonitis.
Eur J Surg Suppl.
Chromik AM, Meiser A, Hölling J, Sülberg D, Daigeler A, Meurer K, et al.
Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit.
Herzog T, Chromik AM, Uhl W.
Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria.
Eur J Med Res.
Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, et al.
The microbiology of postoperative peritonitis.
Mulier S, Penninckx F, Verwaest C, Filez L, Aerts R, Fieuws S, et al.
Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients.
Ordoñez CA, Puyana JC.
Management of peritonitis in the critically ill patient.
Surg Clin North Am.
Seguin P, Fédun Y, Laviolle B, Nesseler N, Donnio PY, Mallédant Y.
Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care.
Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse JP, et al.
Risk factors for multi drug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis.
Montravers P, Chalfine A, Gauzit R, Lepape A, Pierre Marmuse J, Vouillot C, et al.
Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections.
Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al.
Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.
Cardoso T, Almeida M, Friedman ND, Aragão I, Costa-Pereira A, Sarmento E, et al.
Classification of healthcare-associated infection: a systematic review 10 years after the first proposal.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.
Esteban A, Frutos-Vivar F, Ferguson ND, Peñuelas O, Lorente JA, Gordo F, et al.
Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward.
Sartelli M, Catena F, Di Saverio S, Ansaloni L, Malangoni M, Moore EE, et al.
Current concept of abdominal sepsis: WSES position paper.
World J Emerg Surg.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.
The Third International Consensus Definitions for Sepsis and Septic Shock Sepsis-3 JAMA.
Cain SE, Kohn J, Bookstaver PB, Albrecht H, Al-Hasan MN.
Stratification of the impact of inappropriate empirical antimicrobial therapy for Gram-negative bloodstream infections by predicted prognosis.
Guirao X, Arias J, Badía JM, García-Rodríguez JA, Mensa J, Alvarez-Lerma F, et al.
Recommendations in the empiric anti-infective agents of intra-abdominal infection.
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.
Surg Infect Larchmt 2010; 11:79—109.
Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, et al.
Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.
Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, et al.
The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary.
Surg Infect Larchmt 2002; 3:161—173.
Sartelli M, Viale P, Catena F, Ansaloni L, Moore E, Malangoni M, et al.
World J Emerg Surg.
Sartelli M, Viale P, Koike K, Pea F, Tumietto F, Van Goor H, et al.
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.
World J Emerg Surg.
Chow AW, Evans GA, Nathens AB, Ball CG, Hansen G, Harding GK, et al.
Canadian practice guidelines for surgical intra-abdominal infections.
Can J Infect Dis Med Microbiol.
Gomi H, Solomkin JS, Takada T, Strasberg SM, Pitt HA, Yoshida M, et al.
TG13 antimicrobial therapy for acute cholangitis and cholecystitis.
J Hepatobiliary Pancreat Sci.
Guidelines for management of intra-abdominal infections.
Anaesth Crit Care Pain Med.
Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al.
Initiation of inappropriate antimicrobial therapy results in a five-fold reduction of survival in human septic shock.
Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al.
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system.
Al-Hasan MN, Eckel-Passow JE, Baddour LM.
Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study.
Eur J Clin Microbiol Infect Dis.
Ruppé E, Armand-Lefèvre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y, et al.
High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After ravel to the Tropics.
Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
Montravers P, Augustin P, Grall N, Desmard M, Allou N, Marmuse JP, Guglielminotti J.
Characteristics and outcomes of anti-infective de-escalation during health care-associated подробнее на этой странице infections.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR.
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al.
International study of the prevalence and outcomes of infection in intensive care units.
De Waele J, Lipman J, Sakr Y, Marshall JC, Vanhems P, Barrera Groba C, et al.
Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome.
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al.
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.
Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L.
Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.
Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al.
Edusepsis Study Group: Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study.
Am J Respir Crit Care Med.
Castellanos-Ortega A, Suberviola B, García-Astudillo LA, Holanda MS, Ortiz F, Llorca J, et al.
Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study.
Puskarich MA, Trzeciak S, Shapiro NI, Arnold RC, Horton JM, Studnek JR, et al.
Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol.
Rello J, Vidaur L, Sandiumenge A, Rodriguez A, Gualis B, Boque C, et al.
De-escalation therapy in ventilator-associated pneumonia.
Alvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan JM, Quintana E, et al.
Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study.
Eachempati SR, Hydo LJ, Shou J, Barie PS.
Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
Garnacho-Montero J, Gutiérrez-Pizarraya 4, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, et al.
De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.
Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanèse J, Jaber S, et al.
De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.
Silva BN, Andriolo RB, Atallah AN, Salomão R.
De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock.
Cochrane Database Syst Rev.
Madaras-Kelly K, Jones M, Remington R, Caplinger C, Huttner B, Samore M.
Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data.
Cisneros JM, Neth O, Gil-Navarro MV, Lepe JA, Jiménez-Parrilla F, Cordero E, et al.
Global impact of an educational antimicrobial stewardship programme on prescribing practice in a tertiary hospital centre.
Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, et al.
Safety and clinical outcomes of carbapenem de-escalation as part of anantimicrobial stewardship programme in 4 ESBL-endemic setting.
Tucker CE, Lockwood AM, Nguyen NH.
Antibiotic dosing in obesity: the search for optimum dosing strategies.
Hackel MA, Badal RE, Bouchillon SK, Biedenbach DJ, Hoban DJ.
Resistance rates of intra-abdominal isolates from intensive care units and non-intensive care units in the United States: the study for monitoring antimicrobial resistance trends 2010—2012.
Surg Infect Larchmt 2015; 16:298—304.
Powell LL, Wilson SE.
The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.
Surg Infect Larchmt 2000; 1:57—63.
Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM.
Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998—2007.
Johnson JR, Owens K, Gajewski A, Clabots C.
Escherichia coli colonization patterns among human household members and pets, with attention to acute urinary tract infection.
Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG.
Expert Rev Anti Infect Ther.
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME.
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis.
Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al.
Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia.
Harris PN, Tambyah PA, Paterson DL.
Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
Garbino J, Villiger P, Caviezel A, Matulionyte R, Uckay I, Morel P, et al.
A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections.
Henry X, Amoroso A, Coyette J, Joris B.
Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium.
Liapikou A, Cillóniz C, Torres A.
Ceftobiprole for адрес страницы treatment of pneumonia: a European perspective.
Drug Design, Development and Therapy.
Queenan AM, Shang W, Kania M, Page MG, Bush K.
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
Falagas ME, Matthaiou DK, Bliziotis IA.
Systematic по этому сообщению Fluoroquinolones for the treatment of intra-abdominal surgical infections.
Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T.
Quinolones: A practical review of clinical uses, dosing considerations, and drug interactions.
Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, et al.
Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR.
Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly Вызывная панель HIKVISION IP панель на одного абонента с />Infect Control Hosp Epidemiol.
Antibiotic utilization: is there an effect on antimicrobial resistance?
Sartelli M, Catena F, Coccolini F, Pinna AD.
Antimicrobial management of intra-abdominal infections: literature's guidelines.
Falagas ME, Peppas G, Makris GC, Karageorgopoulos DE, Matthaiou DK.
Meta-analysis: Ertapenem for complicated intra-abdominal infections.
Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M.
Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa.
Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al.
Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.
Trivedi M, Patel V, Soman R, Rodriguez C, Singhal T.
The outcome of treating ESBL infections with carbapenems vs.
J Assoc Physicians India.
Dupont H, Carbon C, Carlet J.
Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an https://realgost.ru/panel/bra-idlamp-846-8461a-blackchrome.html in treatment of severe generalized peritonitis: a multicenter 4 controlled trial.
The Severe Generalized Peritonitis Study Group.
Heizmann WR, Löschmann PA, Eckmann C, Von Eiff C, Bodmann KF, Petrik C.
Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD.
All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials.
Int J Antimicrob Agents.
Bassetti M, McGovern PC, Wenisch C, Meyer RD, Yan JL, Wible M, et al.
Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
Int J Antimicrob Agents.
Montravers P, Dupont H, Bedos JP, Bret P.
Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting.
Eckmann C, Montravers P, Bassetti M, Bodmann KF, Heizmann WR, Sánchez García M, et al.
Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
Chen YH, Hsueh PR.
Changing bacteriology of abdominal and surgical sepsis.
Curr Opin Infect Dis.
Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL.
Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.
De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al.
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.
Falagas ME, Rafailidis PI.
Expert Opin Investig Drugs.
Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G.
Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible POS gram-negative bacteria.
Eur J Clin Microbiol Infect Dis.
Ruiz J, Núñez ML, Pérez J, Simarro E, Martínez-Campos L, Gómez J.
Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period.
Eur J Clin Microbiol Infect Dis.
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-WittelI M, et al.
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia VAP with intravenous colistin: a comparison with imipenem-susceptible VAP.
Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al.
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, et al.
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al.
Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
Int J Antimicrob Agents.
Michalopoulos AS, Livaditis IG, Gougoutas V.
The revival of fosfomycin.
Int J Infect Dis.
Reffert JL, Smith WJ.
Fosfomycin for the treatment of resistant gram-negative bacterial infections.
Insights from the Society of Infectious Diseases Pharmacists.
Eckmann C, Solomkin J.
Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al.
Mawal Y, Critchley IA, Riccobene TA, Talley AK.
Ceftazidime-avibactam for читать статью treatment of complicated urinary tract infections and complicated intra-bdominal infections.
Expert Rev Clin Pharmacol.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al.
Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection—results from a randomized, controlled, double-blind, phase 3 program.
Liscio Больше на странице, Mahoney MV, Hirsch EB.
Int J Antimicrob Agents.
Holden MT, Hsu LY, Kurt K, Weinert LA, Mather AE, Harris SR, et al.
A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic.
Drug Des Devel Ther.
Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al.
Candida as a risk factor for mortality in peritonitis.
Zappella N, Desmard M, Chochillon C, Ribeiro-Parenti L, Houze S, Marmuse JP, et al.
Positive peritoneal fluid fungal cultures in postoperative peritonitis after bariatric surgery.
Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O.
A multicentre study of antifungal strategies and outcome of Candida spp.
Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Извиняюсь, ZO-GCC-172 карминно-розовый 8 гр следовало JE, et al.
Clinical practice guidelines for the management of candidiasis: мне Вызывная панель DVC-405 весьма update by the Infectious Diseases Society of America.
Playford EG, Webster AC, Sorrell TC, Craig JC.
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH.
Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis.
Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME.
Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials.
Cruciani M, De Lalla F, Mengoli C.
Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis.
Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al.
ESCMID Fungal Infection Study Group.
Knitsch W, Vincent JL, Utzolino S, François B, Dinya T, Dimopoulos G, et al.
A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections.
Allou N, Allyn J, Montravers P.
When and how to cover for fungal infections in patients with severe sepsis and septic shock.
Curr Infect Dis Rep.
Shields RK, Nguyen MH, Press EG, Clancy CJ.
Abdominal candidiasis is a hidden reservoir of echinocandin resistance.
Müller M, Dela Peña A, Derendorf H.
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.
Gonzalez D, Schmidt S, Derendorf H.
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.
Seguin P, Verdier MC, Chanavaz C, Engrand C, Laviolle B, Donnio PY, et al.
Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis.
Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA.
Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
Dahyot-Fizelier C, Lefeuvre S, Laksiri L, Marchand S, Sawchuk RJ, Couet W, et al.
Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis.
Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al.